Gemtaz Dosage & Drug Information

Concise Prescribing Info

Contents

Gemcitabine HCl

Indications/Uses

Advanced NSCLC, pancreatic & advanced bladder cancer; 2nd or subsequent line in advanced ovarian cancer resistant to taxane derivative.

Dosage/Direction for Use

Adult NSCLC 1,000 mg/m² on days 1, 8 & 15; repeat cycle every 28 days. Pancreatic cancer 1,000 mg/m² wkly for up to 7 wk followed by 1 wk rest; then wkly for 3 wk out of every 4 wk. Ovarian cancer 1,000 mg/m² on days 1 & 8; repeat cycle every 21 days. Bladder cancer 1,000 mg/m² IV once wkly for 3 wk; repeat cycle every 4 wk.

Special Precautions

Increased toxicity w/ prolonged infusion time & increased dosing frequency. Monitor platelet, leucocyte & granulocyte counts. Renal or hepatic impairment. Pregnancy, lactation.

Adverse Reactions

Anemia, leucopenia, thrombocytopenia, nausea, vomiting, dyspepsia, fatigue, vertigo, headache, eczema, rash, abdominal & back pain, fever, chills, myalgia, asthenia, anorexia, cough, rhinitis, malaise, sweating, insomnia, alopecia, somnolence, diarrhea, oral toxicity, constipation; peripheral, facial & pulmonary edema.

View ADR Monitoring Form

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01BC05 - gemcitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.

Thai FDA Category

Presentation/Packing

Form

Gemtaz powd for inj 1 g

Packing/Price

1's

Form

Gemtaz powd for inj 200 mg

Packing/Price

1's

Gemtaz

gemcitabine

Manufacturer:

Sun Pharma

Distributor:

DKLL

Marketer:

Ranbaxy